PDCD1 and bladder transitional cell carcinoma: Our genomic data analysis of the TCGA-BLCA cohort indicated a lower TMB in the HR subgroup than in the LR subgroup (p = 0.043; Figure 9F), implying that LR subgroup patients are more likely to benefit from anti-PD-1/PD-L1 immunotherapy.